A series of studies showed that aberrantly activated FoxM1 is closely associated with poor survival of clinical patients with breast cancer, ovarian cancer, bladder cancer, hepatocellular carcinoma, colorectal cancer2 and so on. This evidence concerns the gene FOXM1 and breast cancer.